The endocrines FGF19, FGF21, and FGF23, have great potential to be important therapeutics for a variety of human diseases such as obesity, type II diabetes, and kidney and cardiovascular diseases (4). This evidence concerns the gene FGF21 and obesity due to melanocortin 4 receptor deficiency.